Singapore markets open in 1 hour 16 minutes
  • Straits Times Index

    3,365.67
    -12.62 (-0.37%)
     
  • S&P 500

    4,076.60
    +58.83 (+1.46%)
     
  • Dow

    34,086.04
    +368.95 (+1.09%)
     
  • Nasdaq

    11,584.55
    +190.74 (+1.67%)
     
  • BTC-USD

    23,128.19
    +320.82 (+1.41%)
     
  • CMC Crypto 200

    519.63
    +0.84 (+0.16%)
     
  • FTSE 100

    7,771.70
    -13.17 (-0.17%)
     
  • Gold

    1,943.00
    -2.30 (-0.12%)
     
  • Crude Oil

    79.10
    +0.23 (+0.29%)
     
  • 10-Yr Bond

    3.5290
    -0.0220 (-0.62%)
     
  • Nikkei

    27,327.11
    -106.29 (-0.39%)
     
  • Hang Seng

    21,842.33
    -227.40 (-1.03%)
     
  • FTSE Bursa Malaysia

    1,485.50
    -13.89 (-0.93%)
     
  • Jakarta Composite Index

    6,839.34
    -33.14 (-0.48%)
     
  • PSE Index

    6,793.25
    -177.72 (-2.55%)
     

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $165.99, marking a +0.36% move from the previous day. This change lagged the S&P 500's 0.75% gain on the day. At the same time, the Dow added 0.55%, and the tech-heavy Nasdaq lost 0.01%.

Heading into today, shares of the drugmaker had gained 12.04% over the past month, outpacing the Medical sector's gain of 5.42% and the S&P 500's gain of 3.49% in that time.

Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.67 per share. This would mark year-over-year growth of 10.88%. Meanwhile, our latest consensus estimate is calling for revenue of $15.38 billion, up 3.29% from the prior-year quarter.

ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.86 per share and revenue of $58.31 billion. These results would represent year-over-year changes of +9.13% and +3.76%, respectively.

Investors should also note any recent changes to analyst estimates for AbbVie. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% lower. AbbVie is holding a Zacks Rank of #3 (Hold) right now.

Valuation is also important, so investors should note that AbbVie has a Forward P/E ratio of 11.93 right now. This valuation marks a discount compared to its industry's average Forward P/E of 15.08.

Also, we should mention that ABBV has a PEG ratio of 4.71. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABBV's industry had an average PEG ratio of 2.03 as of yesterday's close.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 25% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research